Abbisko Cayman Limited (2256) AI Stock Analysis

• Market Cap: HK$8.50B
• Dividend Yield: N/A
• Average Volume (3M): 4.32M
• Price to Earnings (P/E): 44.7
• Beta (1Y): 1.36
• Revenue Growth: 23.37%
• EPS Growth: N/A
• Country: HK
• Employees: 281
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.57
• Shares Outstanding: 680,105,350
• 10 Day Avg. Volume: 4,319,715
• 30 Day Avg. Volume: 4,318,146
• PEG Ratio: -1.02
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 6.07
• P/FCF Ratio: -150.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$22.60
• Price Target Upside: 73.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: HK$13.00 ▼(-0.15% Downside)

Abbisko Cayman Limited's overall stock score is primarily influenced by its financial performance, which shows promising revenue growth and improved net income. However, technical indicators suggest bearish momentum, and the stock's high P/E ratio indicates potential overvaluation. The absence of a dividend yield further impacts its valuation negatively.

Positive Factors

Sustained Revenue Growth

Consistent, sizable revenue growth in 2024 indicates the company is advancing product commercialization or partnership monetization. Over a 2–6 month horizon this supports continued investment in R&D and operations, improving the likelihood of sustained scale and partner confidence.

Conservative Capital Structure

A low leverage profile provides durable financial flexibility for a biotech with development-stage cash needs. It reduces refinancing risk, preserves capacity to fund trials or licensing activities, and lowers interest burden, strengthening the company’s multi-month funding runway.

High Gross Margin and Improved Net Income

A 100% gross margin implies revenues have negligible direct cost, delivering strong operating leverage as fixed R&D and SG&A are absorbed. The 2024 net income improvement signals the business can reach profitability if revenue growth and expense control persist over coming quarters.

Negative Factors

Negative Operating Cash Flow

Ongoing negative operating cash flow shows operations aren’t self-funding and the company likely needs external financing or milestone receipts to run clinical programs. This structural cash burn raises funding risk and constrains strategic optionality over the medium term.

Historic Negative EBIT/EBITDA Margins

Persistent negative operating profitability suggests core cost base (R&D, SG&A) outpaces earned revenues, risking recurring losses if revenues don’t continue growing. Over months this can erode reserves and pressure management to reprioritize programs or seek dilutive funding.

Revenue Concentration on Milestones/Licensing

Heavy reliance on milestone and licensing receipts creates lumpy, event-driven revenue that reduces predictability and cash visibility. Structural dependence on partner timelines and trial outcomes increases volatility in funding and makes multi-month planning and sustained organic growth harder.

Abbisko Cayman Limited Business Overview & Revenue Model

Company Description

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Abbisko Cayman Limited generates revenue through a multi-faceted approach that includes the development and commercialization of its proprietary drug candidates. The company's primary revenue streams consist of milestone payments from pharmaceutical partnerships, licensing agreements for drug candidates, and potential royalties from sales of products developed in collaboration with other biotech firms or pharmaceutical companies. Significant partnerships with larger pharmaceutical companies enhance Abbisko's financial stability by providing upfront payments and shared development costs, which contribute to its earnings as they progress through clinical trials and regulatory approvals.

Abbisko Cayman Limited Financial Statement Overview

Summary

Abbisko Cayman Limited has shown significant revenue growth and improved net income in the latest year, indicating potential for future profitability. The balance sheet is strong with low debt and high equity, but the company must continue to manage its cash flows effectively to ensure long-term sustainability. The recent improvements in financial performance are promising, but sustained effort is required to maintain and build upon this progress.

Income Statement

Abbisko Cayman Limited has shown a substantial increase in revenue in 2024 compared to 2023. The gross profit margin is 100% for both years, indicating all revenue contributes directly to profit before expenses. However, despite revenue growth, the company has struggled with profitability, as reflected by negative EBIT and EBITDA margins in recent years, although net income turned positive in 2024, indicating some improvement.

Balance Sheet

The company maintains a strong equity position with a very low debt-to-equity ratio, indicating limited reliance on debt financing. The equity ratio is high, suggesting strong financial stability. However, the return on equity is low due to prior years of negative net income, although there was a positive turn in 2024 which indicates some improvement in leveraging equity for profits.

Cash Flow

Operating cash flow remains negative, indicating that the business is not generating sufficient cash from operations. However, free cash flow has improved in 2024 compared to 2023, suggesting better cash management. The company has also reduced its capital expenditures, which might have helped in improving free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	618.84M	503.99M	19.06M	0.00	22.68M	0.00
Gross Profit	618.84M	503.99M	19.06M	0.00	22.68M	0.00
EBITDA	96.28M	-15.28M	-410.99M	-492.62M	-1.80B	-150.21M
Net Income	149.98M	28.30M	-431.58M	-498.29M	-1.81B	-706.81M
Balance Sheet
Total Assets	2.44B	2.11B	2.12B	2.49B	2.65B	665.97M
Cash, Cash Equivalents and Short-Term Investments	2.38B	2.01B	1.96B	2.35B	2.57B	636.66M
Total Debt	17.77M	24.29M	35.72M	45.58M	53.80M	4.31M
Total Liabilities	217.96M	148.71M	134.28M	143.16M	118.48M	1.77B
Stockholders Equity	2.22B	1.96B	1.98B	2.35B	2.54B	-1.10B
Cash Flow
Free Cash Flow	126.03M	-20.32M	-456.98M	-366.64M	-182.08M	-121.60M
Operating Cash Flow	129.00M	-12.92M	-444.73M	-343.90M	-169.74M	-117.56M
Investing Cash Flow	239.41M	-196.50M	378.52M	-216.57M	-1.46B	-11.25M
Financing Cash Flow	23.09M	-80.86M	-16.11M	-20.81M	2.10B	505.89M

Abbisko Cayman Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2256, the sentiment is Negative. The current price of 13.02 is below the 20-day moving average (MA) of 13.90, below the 50-day MA of 13.83, and above the 200-day MA of 12.86, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 33.82 is Neutral, neither overbought nor oversold. The STOCH value of 16.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2256.

Abbisko Cayman Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2256	57 Neutral	HK$8.50B	44.66	6.73%	―	23.37%	―
1672	54 Neutral	HK$13.69B	-48.42	-12.74%	―	-76.58%	-4.90%
9966	53 Neutral	HK$8.68B	33.97	13.34%	―	206.58%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2142	51 Neutral	HK$10.51B	16.10	35.80%	―	59.70%	239.97%
2616	42 Neutral	HK$7.80B	-17.23	-95.84%	―	-55.64%	-158.67%

Abbisko Cayman Limited Corporate Events

Abbisko’s TGCT Drug Pimicotinib Wins FDA NDA Acceptance After Strong Phase III Data

Abbisko Cayman Limited announced that its subsidiary Abbisko Therapeutics has had its New Drug Application for pimicotinib, an orally administered and highly selective CSF-1R inhibitor for the systemic treatment of tenosynovial giant cell tumor, formally accepted by the US Food and Drug Administration. Pimicotinib, already approved in China and licensed globally to Merck KGaA, Darmstadt, Germany, is backed by positive Phase III MANEUVER trial data showing statistically significant improvements in tumor response and patient-reported outcomes, positioning the drug as a potential new once-daily standard of care for TGCT and marking a major milestone in Abbisko’s international expansion despite the company’s caution that ultimate commercialization is not guaranteed.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Wins NMPA IND Clearance for Novel KRAS G12D Cancer Drug ABSK141

Abbisko Cayman Limited announced that its subsidiary Abbisko Therapeutics has received clearance from China’s National Medical Products Administration for an Investigational New Drug application to begin clinical trials of ABSK141, an oral, highly potent and selective small-molecule inhibitor targeting KRAS G12D mutations in patients with advanced solid tumors. The open-label Phase I/II study will evaluate the safety, tolerability, efficacy and pharmacokinetics of ABSK141 in cancers such as pancreatic, colorectal and non-small cell lung cancer, positioning Abbisko in the competitive race to develop the first targeted therapy against the notoriously difficult KRAS G12D mutation and potentially strengthening its profile in precision oncology, though the company cautions there is no guarantee the drug will ultimately reach the market.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Wins First Global Approval for TGCT Drug Pimicotinib in China

Abbisko Cayman Limited announced that its subsidiary Abbisko Therapeutics has received approval from China’s National Medical Products Administration for pimicotinib, a novel, oral, highly selective CSF-1R inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor where surgery would likely cause significant functional impairment or morbidity. The drug, the first domestically developed systemic therapy for TGCT and the first regulatory approval for pimicotinib worldwide, was approved on the strength of positive global Phase III MANEUVER trial data showing a markedly higher objective response rate than placebo and meaningful improvements in pain, stiffness, physical function and range of motion; the swift, zero-deficiency review and successful overseas site inspection underscore regulators’ confidence in Abbisko’s R&D standards and mark a key milestone toward the company’s first product commercialization in partnership with Merck, which is now working to secure timely patient access in China, although the company cautions that ultimate commercial success is not guaranteed.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Therapeutics Advances FGFR2/3 Inhibitor for Achondroplasia Treatment

Abbisko Therapeutics has announced the successful dosing of the first patient in a Phase II clinical study for ABSK061, a selective FGFR2/3 inhibitor, aimed at treating achondroplasia in children. This development marks a significant step in addressing the genetic disorder, which affects growth in children, by potentially offering a more effective treatment option with fewer side effects compared to existing therapies.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Therapeutics Reports Positive Phase II Results for NSCLC Treatment

Abbisko Therapeutics has announced promising preliminary results from a Phase II clinical study of its oral PD-L1 inhibitor, ABSK043, in combination with the EGFR inhibitor firmonertinib, for treating non-small cell lung cancer (NSCLC). The study, presented at the ESMO Asia 2025, demonstrated favorable safety and tolerability, with no dose-limiting toxicities observed. The combination showed promising anti-tumor activity, achieving a 71% disease control rate. These findings suggest a potential new treatment strategy for NSCLC patients with EGFR mutations and high PD-L1 expression, addressing a significant unmet need in this patient population.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Therapeutics Secures FDA Clearance for Pioneering Cancer Drug

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has received clearance from the U.S. FDA for its Investigational New Drug application for ABSK141, a novel oral small-molecule KRAS G12D inhibitor. This development marks a significant step in addressing the challenging KRAS G12D mutation found in various solid tumors, including pancreatic, colorectal, and non-small cell lung cancers. The IND clearance allows Abbisko to proceed with Phase I/II clinical trials to evaluate the drug’s safety and efficacy, potentially strengthening its position in the oncology pharmaceutical industry.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$15.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Therapeutics Showcases Promising Phase III Results for TGCT Treatment

Abbisko Therapeutics, a subsidiary of Abbisko Cayman Limited, presented promising long-term efficacy and safety results from its Phase III MANEUVER study of pimicotinib at the CTOS 2025 Annual Meeting. The study demonstrated significant improvements in tumor response and patient quality of life, reinforcing pimicotinib’s potential for long-term use in TGCT patients. The results highlight the drug’s robust and durable response, with a notable increase in objective response rate and quality of life improvements over time, positioning Abbisko as a key player in the TGCT treatment landscape.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

Abbisko Therapeutics Advances Phase II Study for NSCLC Treatment

Abbisko Cayman Limited announced that its subsidiary, Abbisko Therapeutics, has completed the first patient dosing in a Phase II clinical study of ABSK043, an oral small-molecule PD-L1 inhibitor, in combination with Glecirasib for treating non-small cell lung cancer (NSCLC) with KRAS G12C mutation. This milestone marks a significant advancement in the development of this treatment regimen, which aims to address a prevalent oncogenic driver in human cancer. The study, approved by China’s National Medical Products Administration, seeks to evaluate the safety and efficacy of this novel combination therapy, potentially impacting the company’s market positioning and offering new hope for patients with advanced NSCLC.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.